These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28161839)

  • 1. Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients.
    Moldovan D; Rusu C; Potra A; Moldovan I; Patiu IM; Gherman-Caprioara M; Kacso IM
    Int Urol Nephrol; 2017 May; 49(5):895-901. PubMed ID: 28161839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of serum osteoprotegerin and osteoporosis in postmenopausal hemodialysis patients: a pilot study.
    Wu WT; Lee RP; Wang CH; Fang TC; Lin NT; Chen IH; Hsu BG
    J Womens Health (Larchmt); 2010 Apr; 19(4):785-90. PubMed ID: 20210559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients.
    Zheng CM; Chu P; Wu CC; Ma WY; Hung KC; Hsu YH; Lin YF; Diang LK; Lu KC
    Tohoku J Exp Med; 2012 Jan; 226(1):19-27. PubMed ID: 22156488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
    Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
    Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Osteoprotegerin Level Is Negatively Associated with Bone Mineral Density in Patients Undergoing Maintenance Hemodialysis.
    Lu CW; Wang CH; Hsu BG; Tsai JP
    Medicina (Kaunas); 2021 Jul; 57(8):. PubMed ID: 34440966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients.
    Sit D; Kadiroglu AK; Kayabasi H; Atay AE; Yilmaz Z; Yilmaz ME
    Adv Ther; 2007; 24(5):987-95. PubMed ID: 18029324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse Association Between Serum Osteoprotegerin and Bone Mineral Density in Renal Transplant Recipients.
    Hsu BG; Chen YC; Ho GJ; Shih MH; Chou KC; Lin TY; Lee MC
    Transplant Proc; 2016 Apr; 48(3):864-9. PubMed ID: 27234754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density in patients on maintenance hemodialysis and effect of chronic hepatitis C virus infection.
    Yücel AE; Kart-Köseoglu H; Isiklar I; Kuruinci E; Ozdemir FN; Arslan H
    Ren Fail; 2004 Mar; 26(2):159-64. PubMed ID: 15287200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis.
    Delgado-Frías E; López-Mejias R; Genre F; Ubilla B; Gómez Rodríguez-Bethencourt MA; González-Díaz A; de Vera-González AM; González-Rivero AF; Díaz-González F; González-Gay MA; Ferraz-Amaro I
    Clin Exp Rheumatol; 2015; 33(2):241-9. PubMed ID: 25797915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid-femoral pulse wave velocity in hemodialysis patients: a cross sectional study.
    Hou JS; Lin YL; Wang CH; Lai YH; Kuo CH; Subeq YM; Hsu BG
    BMC Nephrol; 2019 May; 20(1):184. PubMed ID: 31122190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD.
    Pobeha P; Petrasova D; Tkacova R; Joppa P
    Respir Med; 2014 Apr; 108(4):621-7. PubMed ID: 24424018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteoprotegerin and bone mineral density in patients with chronic obstructive pulmonary disease].
    Kochetkova EA; Nevzorova VA; Maĭstrovskaia IuV; Massard G
    Ter Arkh; 2010; 82(8):10-4. PubMed ID: 20873238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of osteoprotegerin in vascular disorders of the end-stage renal disease patients.
    Moldovan D; Kacso IM; Rusu C; Potra A; Bondor CI; Moldovan I; Patiu IM; Vladutiu D; Caprioara MG
    Biomarkers; 2015 Mar; 20(2):116-22. PubMed ID: 25585925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.
    Fahrleitner-Pammer A; Dobnig H; Dimai HP; Holzer H; Benesch T; Borchhardt K; Cejka D; Haas M
    Clin Nephrol; 2009 Jun; 71(6):652-9. PubMed ID: 19473634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Stathakis CP; Diamanti-Kandarakis E; Dimitroulis D; Perrea DN
    J Bone Miner Metab; 2008; 26(1):66-72. PubMed ID: 18095066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.
    Hofbauer LC; Schoppet M; Christ M; Teichmann J; Lange U
    Rheumatology (Oxford); 2006 Oct; 45(10):1218-22. PubMed ID: 16574701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
    Grzegorzewska AE; Mlot M
    Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.